Immune checkpoints are regulators of the immune system. The interaction between PD-L1 (red molecule) on the surface of a cancer cell (red) and the immune checkpoint PD-1 (blue molecule) on a T-cell ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system. In this way, the body presumably curbs ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Please provide your email address to receive an email when new articles are posted on . The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target tumors. Despite their initial clinical success, many patients eventually ...

A University of Massachusetts Amherst researcher has received funding from the National Cancer Institute (NCI) to study the complex relationship between drugs used to treat metastatic cancer and the ...

Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer (NK) cells in an animal model, a study led ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2 nd - and 3 rd-line ...